Bromocriptine for Weaning
While bromocriptine 2.5 mg twice daily for 14 days is effective for lactation suppression, cabergoline is the preferred dopamine agonist due to superior tolerability, simpler dosing (single 1 mg dose), and significantly lower rates of rebound lactation and adverse events 1.
Bromocriptine Regimen
If bromocriptine must be used (when cabergoline is unavailable):
- Dose: 2.5 mg orally twice daily with food 2
- Duration: 14 days 1, 3
- Timing: Initiate within hours after delivery or when lactation suppression is desired 4
- Efficacy: Complete suppression achieved in 97% of women by day 5, with 73.5% remaining symptom-free through 14 days 3
Critical Precautions and Monitoring
Blood Pressure Monitoring
Blood pressure must be monitored, especially during the first days of treatment 1. The 2025 BJOG guideline emphasizes this is non-negotiable, as dopamine agonists can precipitate:
- Hypertensive crises
- Intracerebral hemorrhage
- Seizures (with or without preceding hypertension)
- Stroke
- Myocardial infarction 2
Contraindications and High-Risk Situations
Bromocriptine is NOT recommended for routine lactation suppression in women with uncontrolled hypertension or pre-eclampsia 1, 2. However, if used after careful risk-benefit discussion in hypertensive patients:
- Monitor blood pressure multiple times daily during the first week
- Watch for severe, progressive, or unremitting headache (with or without visual disturbances)
- Discontinue immediately if hypertension, visual changes, or CNS toxicity develops 2
Common Side Effects
- Nausea, vomiting, dizziness (3% incidence) 3
- Orthostatic hypotension (supine systolic drops of 20+ mmHg in 30% of patients) 2
- Rebound engorgement/secretion (7% incidence) 3
- Take with food to minimize gastrointestinal effects 2
Driving and Machinery
Patients must be warned not to drive or operate machinery during treatment due to documented somnolence and sudden sleep onset episodes 2.
Clinical Context: Why Cabergoline is Superior
The 2025 BJOG guideline (Level 1A evidence) clearly states that in a head-to-head RCT of 272 women, cabergoline demonstrated 1:
- Similar effectiveness to bromocriptine (RR 1.38,95% CI 0.93-2.05 at day 14)
- Significantly lower rebound breast activity
- Significantly fewer adverse events
- Simpler dosing (single 1 mg dose vs. 28 doses over 14 days)
The Cochrane review of 62 trials (6,428 women) confirmed comparable efficacy but noted bromocriptine's higher side effect burden 1.
Special Populations
Peripartum Cardiomyopathy Context
The 2022 AHA/ACC/HFSA guidelines note that bromocriptine's role in peripartum cardiomyopathy (PPCM) remains uncertain and must be accompanied by at least prophylactic anticoagulation due to hypercoagulability risk 5. This is a different indication than routine lactation suppression but highlights the drug's thrombotic potential.
Pregnancy Exposure
If pregnancy occurs during treatment, discontinue bromocriptine immediately unless treating a rapidly expanding macroadenoma, in which case multidisciplinary consultation is mandatory 2.
Practical Algorithm
- First-line: Attempt non-pharmacologic measures (support bra, ice packs, analgesics) 1
- If pharmacologic suppression needed: Use cabergoline 1 mg single dose if available
- If only bromocriptine available:
- Screen for hypertension/pre-eclampsia
- If normotensive: Initiate 2.5 mg PO BID with food × 14 days
- If hypertensive: Discuss risks vs. benefits; if proceeding, implement intensive BP monitoring
- Monitor BP at least daily for first 3-5 days
- Counsel on driving restrictions and warning signs (headache, visual changes)
- Discontinue if BP elevation, severe headache, or neurologic symptoms develop
The evidence strongly favors cabergoline when available; bromocriptine should be reserved for situations where cabergoline is inaccessible and requires vigilant monitoring for cardiovascular complications.